EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cannabidiol Bioavailability Is Nonmonotonic with a Long Terminal Elimination Half-Life: A Pharmacokinetic Modeling-Based Analysis

Aditya R Kolli iD, Julia Hoeng

Cannabis & Cannabinoid Research · 2025

DOI: 10.1089/can.2023.0214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cannabis & Cannabinoid Research, 2025. Verfasst von Aditya R Kolli und 1 weiteren Autor:innen. Beteiligte Einrichtung: PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland. Hauptthemen laut MEDLINE: Cannabidiol, Models, Biological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral and inhalation-based cannabidiol (CBD) administration has been clinically evaluated for various therapeutic indications, alongside widespread off-label use. However, the long-term exposure kinetics and varied bioavailability have not been fully characterized.

Methods

Human CBD plasma concentration–time profiles from six studies evaluating the oral administration of Epidiolex ® and three studies evaluating inhalation-based delivery were obtained. A four-compartment pharmacokinetic (PK) model with Weibull-based oral absorption kinetics was employed to describe the long-term PKs of CBD. Furthermore, a Cedergreen–Ritz–Streibig model was applied to evaluate nonmonotonic oral bioavailability.

Results

CBD was extensively distributed into tissue compartments with varied kinetics resulting in a long plasma terminal elimination half-life of >134 h in humans. For once-a-day oral dosing, the plasma trough concentrations require >70 days to reach a steady state. The oral bioavailability of CBD for different doses administered in fasted state follows a nonmonotonic pattern with an inverted U-shaped profile. Oral administration of CBD under fed state or subjects with hepatic impairment yields higher oral bioavailability with varied exposure. In contrast, inhalation-based delivery of CBD, while delivering a similar systemic delivered dose compared with oral dosing due to high device losses, bypasses first-pass metabolism and can be efficient.

Conclusion

CBD PKs vary across different doses due to nonmonotonic oral bioavailability, and inhalation-based delivery could minimize such variability in humans. The delayed attainment of steady state and prolonged terminal half-life, resulting from differential but extensive tissue distribution, needs to be considered when dosing CBD in the long term. These fundamental findings are critical for establishing dose–exposure relationship for further clinical evaluation of novel CBD-based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolModels, BiologicalHumansHalf-LifeBiological AvailabilityAdministration, OralAdministration, InhalationMaleAdultFemaleMiddle AgedYoung Adult

Stichwörter der Autor:innen

bioavailabilitycannabidiolhalf-lifeinhalationoralpharmacokinetics

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
  • Vectura Fertin Pharma, Basel, Switzerland.

ORCID-Profile: Aditya R Kolli

Zitieren

APA

Kolli, A. R., & Hoeng, J. (2025). Cannabidiol Bioavailability Is Nonmonotonic with a Long Terminal Elimination Half-Life: A Pharmacokinetic Modeling-Based Analysis. Cannabis & Cannabinoid Research. https://doi.org/10.1089/can.2023.0214

Vancouver

Kolli AR, Hoeng J. Cannabidiol Bioavailability Is Nonmonotonic with a Long Terminal Elimination Half-Life: A Pharmacokinetic Modeling-Based Analysis. Cannabis & Cannabinoid Research. 2025. doi:10.1089/can.2023.0214

BibTeX
@article{Kolli2025,
  author = {Kolli, Aditya R and Hoeng, Julia},
  title = {Cannabidiol Bioavailability Is Nonmonotonic with a Long Terminal Elimination Half-Life: A Pharmacokinetic Modeling-Based Analysis},
  journal = {Cannabis & Cannabinoid Research},
  year = {2025},
  doi = {10.1089/can.2023.0214}
}
Kostenlos starten →